Learn More
The PEGylation of colloidal drug carrier systems protects them from a rapid clearance from the blood stream and therefore prolongs their plasma half-lives. This fundamental concept is nowadays widely applied whereas the analytical description, i.e., the quantification of the PEGylation process, is still challenging due to the poor spectrophotometrical(More)
The freeze-drying properties of gelatin nanoparticles were investigated with the goal of providing practicable nanoparticle formulations for in vitro applications or clinical studies. Various excipients and rehydration protocols were assessed, and gelatin nanoparticles loaded with oligonucleotides were successfully freeze-dried and rehydrated. An NF-kappaB(More)
BACKGROUND AND AIMS The transcription factor nuclear factor kappa B (NF-kappaB) has risen as a promising target for anti-inflammatory therapeutics. In the liver, however, NF-kappaB inhibition mediates both damaging and protective effects. The outcome is deemed to depend on the liver cell type addressed. Recent gene knock-out studies focused on the role of(More)
PURPOSE Surface modified gelatin nanoparticles were tested as a potential carrier system for double stranded DNA and RNA oligonucleotides. The results will be discussed with regard to former experiments conducted with single stranded oligonucleotides. METHODS Gelatin nanoparticles were prepared by a two step desolvation method and surface modified by the(More)
Asymmetrical flow field-flow fractionation (AF4) offers unique separation properties for macromolecules, colloids, particles, and even cells from human or animal origin. At the same time the characterization of non viral colloidal drug delivery systems by means of AF4 is barely described in literature. Here, three different analytical tasks investigating(More)
Peak 1 displays the adaptation of the fractionation conditions as described above to the siRNA oligonucleotide. With an increased initial cross-flow intensity the separation from the void peak, inherent to AF4 systems, will be enhanced (peak 2). The higher MW of the siRNA oligonucleotide compared to the ssDNA oligonucleotide permit the application of a 5(More)
  • 1